Guangzhou Wondfo Biotech Co.,Ltd (300482.SZ)
CNY 23.75
(-0.88%)
CNY 23.75
(-0.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -240.75 Million CNY | 39.45% |
| 2022 | -397.61 Million CNY | 4.69% |
| 2021 | -417.17 Million CNY | 49.42% |
| 2020 | -824.81 Million CNY | 5.02% |
| 2019 | -868.37 Million CNY | 12.01% |
| 2018 | -986.9 Million CNY | -194.83% |
| 2017 | -334.73 Million CNY | 40.75% |
| 2016 | -564.95 Million CNY | -20.04% |
| 2015 | -470.64 Million CNY | -226.82% |
| 2014 | -144.01 Million CNY | -66.39% |
| 2013 | -86.54 Million CNY | -536.87% |
| 2012 | -13.58 Million CNY | -167.92% |
| 2011 | 20 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 299.87 Million CNY | 33.34% |
| 2024 Q1 | -552.92 Million CNY | -129.66% |
| 2024 Q2 | 238.43 Million CNY | 143.12% |
| 2023 Q3 | -135.08 Million CNY | 69.32% |
| 2023 Q1 | -185.12 Million CNY | 53.44% |
| 2023 Q2 | -440.34 Million CNY | -137.87% |
| 2023 FY | -240.75 Million CNY | 39.45% |
| 2023 Q4 | -240.75 Million CNY | -78.23% |
| 2022 Q3 | 544.66 Million CNY | 178.54% |
| 2022 FY | -397.61 Million CNY | 4.69% |
| 2022 Q2 | 195.54 Million CNY | 2.1% |
| 2022 Q1 | 191.51 Million CNY | 145.91% |
| 2022 Q4 | -397.61 Million CNY | -173.0% |
| 2021 Q1 | -420.73 Million CNY | 48.99% |
| 2021 FY | -417.17 Million CNY | 49.42% |
| 2021 Q3 | -369.37 Million CNY | 13.98% |
| 2021 Q2 | -429.39 Million CNY | -2.06% |
| 2021 Q4 | -417.17 Million CNY | -12.94% |
| 2020 Q1 | -612.26 Million CNY | 29.49% |
| 2020 Q3 | -998.61 Million CNY | -13.5% |
| 2020 Q4 | -824.81 Million CNY | 17.4% |
| 2020 FY | -824.81 Million CNY | 5.02% |
| 2020 Q2 | -879.82 Million CNY | -43.7% |
| 2019 Q1 | -212.01 Million CNY | 78.52% |
| 2019 FY | -868.37 Million CNY | 12.01% |
| 2019 Q4 | -868.37 Million CNY | -427.01% |
| 2019 Q2 | -197.38 Million CNY | 6.9% |
| 2019 Q3 | -164.77 Million CNY | 16.52% |
| 2018 Q4 | -986.9 Million CNY | -374.63% |
| 2018 Q2 | -306.4 Million CNY | -12.95% |
| 2018 Q1 | -271.27 Million CNY | 18.96% |
| 2018 FY | -986.9 Million CNY | -194.83% |
| 2018 Q3 | -207.93 Million CNY | 32.14% |
| 2017 Q1 | -288.18 Million CNY | 48.99% |
| 2017 FY | -334.73 Million CNY | 40.75% |
| 2017 Q4 | -334.73 Million CNY | -17.78% |
| 2017 Q3 | -284.19 Million CNY | 4.16% |
| 2017 Q2 | -296.54 Million CNY | -2.9% |
| 2016 FY | -564.95 Million CNY | -20.04% |
| 2016 Q3 | -419.65 Million CNY | -11.28% |
| 2016 Q2 | -377.1 Million CNY | -27.13% |
| 2016 Q1 | -296.62 Million CNY | 36.97% |
| 2016 Q4 | -564.95 Million CNY | -34.63% |
| 2015 Q2 | -470.65 Million CNY | -749.61% |
| 2015 FY | -470.64 Million CNY | -226.82% |
| 2015 Q3 | -434.94 Million CNY | 7.59% |
| 2015 Q4 | -470.64 Million CNY | -8.21% |
| 2015 Q1 | -55.39 Million CNY | 61.53% |
| 2014 Q1 | 103.83 Million CNY | 0.0% |
| 2014 Q4 | -144.01 Million CNY | 0.0% |
| 2014 FY | -144.01 Million CNY | -66.39% |
| 2013 FY | -86.54 Million CNY | -536.87% |
| 2012 FY | -13.58 Million CNY | -167.92% |
| 2011 FY | 20 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.31 Billion CNY | 118.262% |
| Hangzhou Tigermed Consulting Co., Ltd. | -4.06 Billion CNY | 94.073% |
| Dirui Industrial Co.,Ltd. | -131.62 Million CNY | -82.917% |
| Beijing Strong Biotechnologies, Inc. | 411.59 Million CNY | 158.494% |
| Medicalsystem Biotechnology Co., Ltd. | -850.71 Million CNY | 71.699% |
| Maccura Biotechnology Co.Ltd | -170.79 Million CNY | -40.965% |
| Guangdong Hybribio Biotech Co.,Ltd. | -708.27 Million CNY | 66.008% |
| BGI Genomics Co., Ltd. | -3.63 Billion CNY | 93.378% |
| Amoy Diagnostics Co., Ltd. | -92.73 Million CNY | -159.629% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -486.57 Million CNY | 50.52% |